(Total Views: 460)
Posted On: 01/15/2021 12:58:25 PM
Post# of 151694
Re: ClosetInvestor #72874
Let met try this another way.
The top line data will be out before the secondary data. I am confident of that.
The Primary endpoint for our SC trial is all cause mortality at 28 days (hence my pulse reference).
This is the simplest evaluation there can be for any endpoint. It is simply not accurate to say that it will take as long to evaluate as any metric that contains multiple measurements.
You seem to be saying that the totality of the endpoints will take the same amount of time as the M2M trial. Ill give you that.
But, at this point in time, I don't care about the secondary endpoints. If the PE data is as good as we think it could be, the SE are not important.
The top line data will be out before the secondary data. I am confident of that.
The Primary endpoint for our SC trial is all cause mortality at 28 days (hence my pulse reference).
This is the simplest evaluation there can be for any endpoint. It is simply not accurate to say that it will take as long to evaluate as any metric that contains multiple measurements.
You seem to be saying that the totality of the endpoints will take the same amount of time as the M2M trial. Ill give you that.
But, at this point in time, I don't care about the secondary endpoints. If the PE data is as good as we think it could be, the SE are not important.
(5)
(0)Scroll down for more posts ▼
